Omega-3 fatty acids supplementation improve nutritional status and inflammatory response in patients with lung cancer: a randomized clinical trial

How to cite

Huo, Qianlun. 2021. "Omega-3 fatty acids supplementation improve nutritional status and inflammatory response in patients with lung cancer: a randomized clinical trial." AEA RCT Registry. AEARCTR-0007165. https://doi.org/10.1257/rct.7165-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Qianlun Huo*

* Primary investigator

Registry ID
AEARCTR-0007165
DOI
https://doi.org/10.1257/rct.7165-1.0
First registered
Last updated
Status
Completed
Trial dates
2019-02-01 – 2020-09-01
Countries
China ()
Registry record
http://www.socialscienceregistry.org/trials/7165

Abstract

Background & aims: Clinical studies have reported positive results with omega-3 supplements in oncologic patients. The aim of this study was to evaluate the efficacy of Omega-3 fatty acids supplementation in improving nutritional status and inflammatory markers of patients with lung cancer.
Methods: In a randomized double blind parallel design trial, sixty patients with lung cancer at nutritional status risk based on Nutrition Risk Screening 2002 were randomized to be allocated to two study groups, receiving omega 3 fatty acids supplement (EPA 1.6 g and DHA 0.8 g) or placebo for 12 weeks. Anthropometric measurements (weight, BMI, upper-arm circumference, and triceps skinfold thickness), nutritional based laboratory indices (hemoglobin, albumin, triglyceride, cholesterol), and inflammatory markers (CRP, TNF alpha, and IL-6) were measured before and after the intervention as study outcomes.

Intervention

Omega-3 fatty acids supplementation gel capsules (EPA 1.6 g and DHA 0.8 g), or placebo gel capsules (sunflower oil) with similar appearance (supplied by Sinadaro, China) were provided to the patients for 12 weeks of intervention. The patients’ compliance was evaluated by a form marked on each day of taking capsules. Patients with more than 3 lost dose was excluded from the analysis.

Experimental design

The study was designed as a double-blinded placebo-controlled randomized clinical trial including two-arms with parallel design. No change was made in methods after trial commencement.

Design details

Randomization method
Sixty eligible patients were randomly allocated to the two study groups by the clinic secretary based on randomization list. The list was created by block randomization method. The oncologist, nutritionist, and secretary all kept blind to patients’ group assignment. Patients also remained blind to the treatment groups by similarity in the shape, colour and size of gel capsules and bottles of omega-3 fatty acids and placebo.
Randomization unit
individual
Clusters
60
Observations
60
Arms
30
Primary outcomes
Anthropometric measurements (weight, BMI, upper-arm circumference, and triceps skinfold thickness), nutritional based laboratory indices (hemoglobin, albumin, triglyceride, cholesterol), and inflammatory markers (CRP, TNF alpha, and IL-6) were measured before and after the intervention as study outcomes.

Cited by

No citation data available for this registration yet.

Keywords